Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.37 |
| ▸ | CD22 | P20273 | 10/20 | 0.35 |
| ▸ | MAG | P20916 | 4/20 | 0.35 |
| ▸ | SELL | P14151 | 1/20 | 0.34 |
| ▸ | SELP | P16109 | 1/20 | 0.34 |
| ▸ | SIGLEC7 | Q9Y286 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18733280 | 0.87 | L3MBTL1 (0.46) | L3MBTL1NANPCD22MAGSELL | |
| SCHEMBL27525510 | 0.85 | L3MBTL1 (0.45) | L3MBTL1NANPCD22MAGSELL | |
| SCHEMBL27728222 | 0.85 | L3MBTL1 (0.45) | L3MBTL1NANPCD22MAGSELL | |
| SCHEMBL9699209 | 0.85 | L3MBTL1 (0.44) | L3MBTL1NANPCD22MAGSELL | |
| SCHEMBL18333560 | 0.84 | NANP (0.50) | L3MBTL1NANPCD22MAGSELL | |
| SCHEMBL18333558 | 0.84 | NANP (0.50) | L3MBTL1NANPCD22MAGSELL | |
| SCHEMBL13190938 | 0.84 | NANP (0.50) | L3MBTL1NANPCD22MAGSELL | |
| SCHEMBL15849913 | 0.84 | NANP (0.50) | L3MBTL1NANPCD22MAGSELL | |
| SCHEMBL8502846 | 0.84 | NANP (0.50) | L3MBTL1NANPCD22MAGSELL | |
| SCHEMBL17546140 | 0.84 | NANP (0.50) | L3MBTL1NANPCD22MAGSELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114258305-A | Type III NKT cells and related compositions and methods | 阿克索治疗公司 | 2022-03-29 | — | — | CN | disclosed |
| US-11248058-B2 | Chimeric antigen receptors and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248058-B2 | Chimeric antigen receptors and uses thereof | CD2, CD22, ICOS | L3MBTL1 2456/4885NANP 1451/4885CD22 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.